文献速递淋巴瘤

PRIMA研究:利妥昔单抗维持治疗滤泡性淋巴瘤的长期无进展生存获益

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.
PubMed 文献 · J Clin Oncol · 2019-07-24

PURPOSE: The PRIMA study (ClinicalTrials.gov identifier: NCT00140582) established that 2 years of rituximab maintenance after first-line immunochemotherapy significantly improved progression-free survival (PFS) in patients with follicular lymphoma compared with observation.…

要点

  • 维持治疗方案为利妥昔单抗375 mg/m2每8周一次,共2年,末次诱导后8周开始。

核心结论

  • 一线免疫化疗后利妥昔单抗维持治疗较观察显著改善长期PFS,但未改善OS。

研究设计与样本

  • PRIMA研究(NCT00140582)为随机对照试验,初治高肿瘤负荷滤泡性淋巴瘤患者接受三种免疫化疗诱导方案之一。
  • 诱导缓解者按1:1随机分配至2年利妥昔单抗维持组(n=505)或观察组(n=513),共1018例完成诱导并随机。

主要发现

  • 未观察到新的安全性信号。

关键数值与推荐

  • 利妥昔单抗维持方案:375 mg/m2,每8周一次,持续2年,于末次诱导治疗后8周开始。

临床怎么用

  • 对于初治高肿瘤负荷滤泡性淋巴瘤经免疫化疗诱导缓解的患者,可考虑2年利妥昔单抗维持治疗以延长PFS。
  • 利妥昔单抗维持治疗未显示OS获益。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The PRIMA study (ClinicalTrials.gov identifier: NCT00140582) established that 2 years of rituximab maintenance after first-line immunochemotherapy significantly improved progression-free survival (PFS) in patients with follicular lymphoma compared with observation. Here, we report the final PFS and overall survival (OS) results from the PRIMA study after 9 years of follow-up and provide a final overview of safety. METHODS: Patients (> 18 years of age) with previously untreated high-tumor-burden follicular lymphoma were nonrandomly assigned to receive one of three immunochemotherapy induction regimens. Responding patients were randomly assigned (stratified by induction regimen, response to induction treatment, treatment center, and geographic region) 1:1 to receive 2 years of rituximab maintenance (375 mg/m2, once every 8 weeks), starting 8 weeks after the last induction treatment, or observation (no additional treatment). All patients in the extended follow-up provided their written informed consent (data cutoff: December 31, 2016). RESULTS: In total, 1,018 patients completed induction treatment and were randomly assigned to rituximab maintenance (n = 505) or observation (n = 513). Consent for the extended follow-up was provided by 607 patients (59.6%) of 1,018 (rituximab maintenance, n = 309; observation, n = 298). After data cutoff, median PFS was 10.5 years in the rituximab maintenance arm compared with 4.1 years in the observation arm (hazard ratio, 0.61; 95% CI, 0.52 to 0.73; P < .001). No OS difference was seen in patients randomly assigned to rituximab maintenance or observation (hazard ratio, 1.04; 95% CI, 0.77 to 1.40; P = .7948); 10-year OS estimates were approximately 80% in both study arms. No new safety signals were observed. CONCLUSION: Rituximab maintenance after induction immunochemotherapy provides a significant long-term PFS, but not OS, benefit over observation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bachy E, Seymour JF, Feugier P, et al. Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. J Clin Oncol. 2019. PMID: 31339826. doi:10.1200/JCO.19.01073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。